Entresto vs Lipitor
A side-by-side look at two cardiovascular medications advertised on TV. Informational only — not medical advice.
| US Entresto | US Lipitor | |
|---|---|---|
| Generic name | sacubitril/valsartan | atorvastatin |
| Drug class | ARNI (Neprilysin Inhibitor + ARB) | Statin |
| Treats | Chronic heart failure | High cholesterol, cardiovascular prevention |
| Category | Cardiovascular | Cardiovascular |
| Manufacturer | Novartis | Pfizer |
| Year approved | 2015 | 1996 |
| FDA warning | Black box warning | No boxed warning |
| Est. TV ad spend | $150M | $60M |
| Common side effects | Low blood pressure, High potassium, Kidney problems, Dizziness | Muscle pain or weakness, Liver problems, Increased blood sugar, Memory problems |
Frequently asked questions
Is Entresto or Lipitor better?
Neither is universally "better." Entresto (sacubitril/valsartan) and Lipitor (atorvastatin) are both used for cardiovascular, but the right choice depends on your medical history, insurance and your doctor's guidance. This comparison is informational only.
What's the difference between Entresto and Lipitor?
Entresto is a ARNI (Neprilysin Inhibitor + ARB) made by Novartis, while Lipitor is a Statin made by Pfizer. See the table above for a side-by-side breakdown.
Which one spends more on TV ads?
Entresto has the larger estimated TV advertising budget of the two.